NYSE:ELANPharmaceuticals
Elanco Animal Health (ELAN) Gains Fresh Momentum As New Launches Feed Its Undervalued Narrative
Elanco Animal Health (ELAN) is back in focus after securing USDA approval for its TruCan Ultra Lyme-L4 canine vaccine and outlining Elanco Ventures, a US$25 million venture platform targeting early stage animal health opportunities.
See our latest analysis for Elanco Animal Health.
Against this backdrop of new products and the Elanco Ventures launch, Elanco Animal Health’s recent momentum has been positive, with a 30 day share price return of 6.79% and a 1 year total shareholder return of...